placeholder image

K. Kubiak All authors

About

Publications While At HealthPartners

selected publications

Journal Article
  • Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. 
  • Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. 
  • Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. 
  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. 

    • Contact

    full name

  • K. Kubiak

    • Quick Info

    Publications

    Collaboration